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Background: Interleukin (IL)-1 inhibitors have been suggested as possible therapeutic
options in a large number of old and new clinical entities characterized by an IL-1 driven
pathogenesis.
Vitale et al. Interleukin (IL)-1 Inhibition in Autoinflammatory and Autoimmune Disorders
Objectives: To perform a nationwide snapshot of the on-label and off-label use of
anakinra (ANA) and canakinumab (CAN) for different conditions both in children and
adults.
Methods: We retrospectively collected demographic, clinical, and therapeutic data from
both adult and pediatric patients treated with IL-1 inhibitors from January 2008 to July
2016.
Results: Five hundred and twenty-six treatment courses given to 475 patients (195
males, 280 females; 111 children and 364 adults) were evaluated. ANA was administered
in 421 (80.04%) courses, CAN in 105 (19.96%). Sixty-two (32.1%) patients had been
treated with both agents. IL-1 inhibitors were employed in 38 different indications (37 with
ANA, 16 with CAN). Off-label use was more frequent for ANA than CAN (p < 0.0001).
ANA was employed as first-line biologic approach in 323 (76.7%) cases, while CAN in
37 cases (35.2%). IL-1 inhibitors were associated with corticosteroids in 285 (54.18%)
courses and disease modifying anti-rheumatic drugs (DMARDs) in 156 (29.65%). ANA
dosage ranged from 30 to 200mg/day (or 1.0–2.0 mg/kg/day) among adults and 2–4
mg/kg/day among children; regarding CAN, the most frequently used posologies were
150mg every 8 weeks, 150mg every 4 weeks and 150mg every 6 weeks. The frequency
of failure was higher among patients treated with ANA at a dosage of 100 mg/day than
those treated with 2 mg/kg/day (p = 0.03). Seventy-six patients (14.4%) reported an
adverse event (AE) and 10 (1.9%) a severe AE. AEs occurred more frequently after the
age of 65 compared to both children and patients aged between 16 and 65 (p = 0.003
and p = 0.03, respectively).
Conclusions: IL-1 inhibitors are mostly used off-label, especially ANA, during
adulthood. The high frequency of good clinical responses suggests that IL-1 inhibitors are
used with awareness of pathogenetic mechanisms; adult healthcare physicians generally
employ standard dosages, while pediatricians are more prone in using a weight-based
posology. Dose adjustments and switching between different agents showed to be
effective treatment strategies. Our data confirm the good safety profile of IL-1 inhibitors.
Keywords: autoinflammatory disorders, treatment, interleukin (IL)-1, anakinra, canakinumab
INTRODUCTION
Inhibition of interleukin (IL)-1 was initially adopted for the
treatment of rheumatoid arthritis (RA). To date, the receptor
antagonist anakinra (ANA), the selective inhibitor of IL-1β
canakinumab (CAN), the soluble decoy IL-1-receptor rilonacept,
and the human-engineered monoclonal anti-IL-1β gevokizumab
represent the four IL-1 inhibitors (IL-1-INH) available (Finch
and Sleeman, 2015). However, only the first two agents, ANA and
CAN, have been approved for clinical use in Europe.
Since its introduction in 2001 for RA, a number of other
inflammatory pathologies have found to benefit from IL-1-
INH, in particularmonogenic autoinflammatory diseases (AIDs),
including familial Mediterranean fever (FMF; Ben-Zvi and
Livneh, 2014; Gül et al., 2015), tumor necrosis factor receptor-
associated periodic syndrome (TRAPS; Brizi et al., 2012; La
Torre et al., 2015; Lopalco et al., 2015b), mevalonate kinase
deficiency/hyper-IgD syndrome (van der Hilst and Frenkel,
2010), and cryopyrin-associated periodic syndrome (CAPS;
Cantarini et al., 2011; Caorsi et al., 2013; Scarpioni et al.,
2015). However, a wide range of polygenic and multifactorial
autoinflammatory conditions characterized by at least a partial
deregulation of IL-1 have recently been described as responsive
to IL-1-INH (Cantarini et al., 2012a,b, 2015c; So et al., 2013;
Cavalli and Dinarello, 2015; Lopalco et al., 2015a). Among
others, adult-onset Still’s disease (AOSD; Naumann et al., 2010;
Nordström et al., 2012), systemic juvenile idiopathic arthritis
(SOJA; Hedrich et al., 2012; Ruperto et al., 2012a,b), Behçet’s
disease (BD; Cantarini et al., 2012a,b, 2015b; Vitale et al.,
2014; Emmi et al., 2016) and crystal-induced arthritis (So
et al., 2007; Schlesinger et al., 2012) are prime examples of
multifactorial AIDs showing a good response to IL-1-INH. As
a whole, an increasing number of disorders have proven to
be characterized by molecular modifications resembling those
found in monogenic AIDs. Therefore, the good clinical response
shown by monogenic AIDs to IL-1-INH induced clinicians to try
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the path of IL-1 inhibition in an increasing number of disorders
previously labeled as possible polygenic AIDs on the basis of
laboratory findings.
Nowadays, in Italy ANA is indicated for the treatment of
RA, in association with methotrexate, and CAPS, while CAN is
indicated for CAPS, SOJA, and gout. Consequently, the use of IL-
1-INH is often done with off-label modality, therefore without
the possibility of real and effective monitoring strategies on long-
term effectiveness and safety. For this reason, we conducted
a multicenter observational study to perform a nationwide
evaluation about the use of IL-1-INH for different conditions
with both on-label and off-label modalities in order to provide
a description of IL-1-INH use in real life and deduce practical
implications as reference points for physicians requiring to use
IL-1-targeted inhibition.
PATIENTS AND METHODS
We retrospectively collected demographic, clinical, and
therapeutic data from both adult and pediatric patients treated
with IL-1-INH from January 2008 to July 2016 in 23 Italian
reference Centers for pediatric and adult patients. Collected data
included patients’ age, gender, disease, disease duration, age at
disease onset, response to IL-1-INH, previous and concomitant
treatments, dosages employed, and modifications of dosages or
frequency of administration, duration of treatment, and causes
for discontinuation, including adverse events (AEs) and severe
AEs (SAEs).
The primary aims of our study were: (i) to identify the
frequency of ANA and CAN prescription as approach in on-
label and off-label use; (ii) to describe the percentage of patients
needing to switch from ANA to CAN and vice versa focusing
the reasons for switching due to AEs, loss of efficacy, primary
inefficacy; (iii) to identify the clinical outcome after switching
from one to another agent; (iv) to investigate whether dosage
adjustments can contribute to the achievement of a secondary
response to treatment; (v) to describe the IL-1-INH safety profile
and identify any correlation between the age of patients and the
occurrence of AEs based to their severity; (vi) to highlight reasons
for discontinuation.
The secondary aims were to describe: (i) different dosages
employed for ANA and CAN, distinguishing between pediatric
and adult subjects; (ii) the number of biologic agents
administered before starting IL-1 inhibition; (iii) previous
and concomitant use of corticosteroids and disease modifying
anti-rheumatic drugs (DMARDs) differentiating by age; (iv)
different therapeutic indications differentiating by age.
Describing the frequency of complete response, partial
response, and failure to IL-1-INH represented an ancillary
end-point.
Response to IL-1-INH was graded as complete, partial, or
failing. The evaluation of response was not standardized,
however the normalization of inflammatory markers
(erythrocyte sedimentation rate, ESR, <15 mm/h; C-reactive
protein, CRP, level <0.5 mg/dl) and the disappearance of all
previously identified signs and symptoms were considered as
criteria for a complete response. Partial response was retained
for patients with clinical improvement, but not fulfilling the
criteria for complete response. Finally, a treatment was labeled as
failing when neither clinical nor laboratory improvements were
observed.
For comparisons between adults and children, patients were
classified as pediatric when aged <16 years.
The study was approved and reviewed by the local Ethical
Committee (AOUS, Azienda Ospedaliera Universitaria Senese)
and was conducted according to the declaration of Helsinki.
Statistical Analysis
Descriptive statistics was evaluated for sample size, mean, and
standard deviation for quantitative variables. For quantitative
data, pair wise comparisons were performed by means of
unpaired t-test for parametric data and Mann-Whitney U-test
for non-parametric data after assessing data normality by using
Anderson–Darling test. For qualitative data comparisons were
performed by means of Chi-square or Fisher’s exact test when
required. Significance was defined as p < 0.05.
RESULTS
We evaluated 526 treatment courses administered to 475 patients
(195 males; 280 females) who underwent IL-1-INH between
January 2008 and July 2016. The mean ± SD age of patients
was of 36.36 ± 22.18 years, the mean ± SD age at symptom
onset and at diagnosis were of 24.47 ± 19.99 and 29.31 ± 20.18
years, respectively. Patients aged <16 years were 111 (23.4%),
corresponding to 135 (25.7%) treatment courses, 93 of which
with ANA (68.9%) and 42 (31.1%) with CAN. The mean ± SD
age of pediatric patients was 10.2 ± 3.8 years (range 1.75–16.0
years). Patients aged more than 16 years were 364. The mean ±
SD age of adults was 44.8± 18.7 (range 16.75–89.0 years).Table 1
shows demographic and clinical data of all patients enrolled, also
distinguishing by different therapeutic indications.
Overall, ANA was administered in 421 (80.04%) courses and
CAN in 105 (19.96%) courses. Sixty-two (32.1%) patients had
been treated with both IL-1-INH. ANA was prescribed on-
label in 60 (14.3%) cases, while CAN was prescribed on-label
in 46 (43.8%) cases. Off-label prescribing was significantly more
frequent for ANA than CAN (p < 0.0001). Figure 1 graphically
describes differences in the on-label use of ANA and CAN.
IL-1-INH were associated with corticosteroids in 285
(54.18%) courses (276 patients, 52.5%) and DMARDs in 156
(29.65%) courses (151 patients, 31.8%). Distinguishing by
age, IL-1-INH plus corticosteroids were administered to 46
(41.4%) pediatric patients, corresponding to 62 (45.2%) pediatric
treatment courses (46 with ANA and 16 with CAN), and 214
(51.6%) adult patients, corresponding to 223 (57.03%) treatment
courses (198 with ANA and 25 with CAN). Concomitant
corticosteroids were significantly more frequently used among
adults than children (p = 0.002). DMARDs plus IL-1-INH
were administered to 27 pediatric patients, corresponding to
32 (23.7%) pediatric treatment courses (23 with ANA and 9
with CAN), and 124 (31.7%) adults, corresponding to 124
(23.6%) treatment courses (115 with ANA and 9 with CAN).
Frontiers in Pharmacology | www.frontiersin.org 3 October 2016 | Volume 7 | Article 380
Vitale et al. Interleukin (IL)-1 Inhibition in Autoinflammatory and Autoimmune Disorders
TABLE 1 | Demographic and clinical data of all patients enrolled in the study.
N◦ patients M (%) Pediatric patients (%) Mean age ± SD
(years)
Age at onset mean
± SD (years)
Age at diagnosis
mean ± SD (years)
Diagnostic delay
mean ± SD (years)
All 475 195 (41.05%) 111 (23.36%) 36.46 ± 22.13 24.44 ± 20.05 29.36 ± 20.19 4.89 ± 9.60
AOSD 78 27 (34.61%) 0 (0%) 47.33 ± 16.03 39.95 ± 16.15 41.82 ± 15.93 1.87 ± 5.38
SOJA 72 34 (47.22%) 53 (73.61%) 11.98 ± 5.29 6.71 ± 4.62 7.07 ± 4.62 0.21 ± 0.43
BD 46 17 (36.95%) 1 (2.17%) 39.54 ± 13.32 27.41 ± 12.60 31.24 ± 12.41 3.83 ± 6.03
RA 42 9 (21.42%) 0 (0%) 67.55 ± 12.51 44.90 ± 12.05 45.95 ± 11.83 1.23 ± 2.21
FMF 34 11 (32.35%) 4 (11.76%) 41.79 ± 19.77 18.96 ± 15.54 36.07 ± 19.31 17.11 ± 15.40
USAID 32 13 (40.62%) 19 (59.37%) 19.42 ± 15.12 8.17 ± 12.87 15.00 ± 14.86 6.83 ± 9.87
CAPS 30 19 (63.33%) 9 (30%) 33.86 ± 21.44 19.22 ± 20.56 28.38 ± 21.77 8.84 ± 13.20
TRAPS 29 12 (41.37%) 3 (10.34%) 39.18 ± 17.25 20.05 ± 15.82 33.68 ± 17.01 13.56 ± 15.23
IRAP 23 13 (56.52%) 4 (17.39%) 40.17 ± 21.43 34.65 ± 22.25 36.17 ± 21.96 1.52 ± 3.98
CRMO 11 3 (27.27%) 6 (54.54%) 13.91 ± 5.01 9.48 ± 5.03 10.59 ± 5.17 1.11 ± 1.75
OTHERS 78 37 (47.43%) 12 (15.38%) 36.46 ± 22.13 24.44 ± 20.05 29.36 ± 20.19 4.73 ± 9.60
AOSD, Adult Onset Still’s Disease; BD, Behçet’s Disease; CAPS, Cryopyrin-Associated Periodic Syndrome; CRMO, Chronic Recurrent Multifocal Osteomyelitis; FMF, Familial
Mediterranean Fever; IRAP, Idiopathic Recurrent Acute Pericarditis; RA, Rheumatoid Arthritis; SOJA, Systemic Onset Juvenile Idiopathic Arthritis; TRAPS, Tumor Necrosis Factor
Receptor-Associated Periodic Syndrome; USAID, Undifferentiated Systemic AutoInflammatory Disease; M, Male; SD, Standard Deviation.
FIGURE 1 | On-label and off-label use of Anakinra (A) and Canakinumab (B). CAPS, Cryopyrin-Associated Periodic Syndrome; RA, rheumatoid arthritis; SOJA,
Systemic Onset Juvenile Idiopathic Arthritis.
Concomitant DMARDs were more frequently administered
in adults, without reaching statistical significance (p = 0.06).
Figure 2 plus Figure 3 and Table 2 better specify concomitant
therapies during IL-1 inhibition.
ANA dosage ranged from 30mg/day subcutaneously to
200 mg/day (or 1.0–2.0 mg/kg/day) among adults and 2–4
mg/kg/day among pediatric patients; however, 18 out of 28
(64.3%) patients aged from 13 to 16 years were administered
the standard dose of 100mg/day, as more frequently described
for adults. One 15-year-old female patient diagnosed with
undifferentiated connective tissue disease and suffering from
macrophage activation syndrome was treated with ANA at a
dosage of 200 mg/day for 8 months. Specifically, the most
frequently employed ANA dosages were as follows: 100mg/day
in 322 out of 421 cases (76.5%) as standard posology, 2mg/kg/day
in 64 patients (15.2%), 1–2mg/kg/day in 18 (4.3%) subjects
based on the patient’s body weight. Regarding CAN, the most
frequently employed posologies were as follows: 150mg every 8
weeks in 41 out of 105 (39.04%) cases; 150mg every 4 weeks in
19 patients (18.1%); 150mg every 6 weeks in 10 patients (9.5%);
4–5 mg/kg every 4 weeks in 11 (10.5%) patients; other dosages
(1–4 mg/kg every 4 weeks, 2 mg/kg every 8 weeks, 300mg every 4
weeks) were employed in 4 (3.8%) subjects. Finally, a patient with
CAPS and a second patient with mevalonate kinase deficiency
were treated with CAN at a dosage of 300mg every 8 weeks and a
2-year-old patient diagnosed with CAPS was treated with CAN
at the dosage of 4 mg/kg every 8 weeks. Figure 4 summarizes
the frequency of administration of different dosages employed for
ANA and CAN.
Regarding response, ANA showed complete effectiveness in
256/421 (60.8%) treatment courses and partial effectiveness
in 116 (27.6%) subjects, while ANA led to no response in
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49 (11.6%). Distinguishing by age, among pediatric patients
ANA was completely effective in 66/93 (71%) cases, partially
effective in 23/93 (24.7%) cases, and led to no response in
4 (4.3%) cases. In adults, ANA was completely effective in
190/328 (57.9%) treatment courses and partially effective in 93
(28.4%), while 45 (13.7%) patients proved no response and 2
(0.6%) were lost at follow-up. Regarding CAN, among children
a complete response was achieved in 26/42 (61.9%) patients,
FIGURE 2 | Use of concomitant therapies during IL-1 inhibition on the
whole of treatment courses. DMARDs, disease modifying antirheumatic
drugs; GCC, glucocorticosteroids; IL-1-INH, IL-1 inhibitors.
while a partial response was obtained in 14 (33.3%) subjects;
failure was identified in 2 (4.8%) patients. Among adults, CAN
led to complete response in 38/63 (60.3%) patients and partial
response in 19 (30.2%), while failure was observed in 6 (9.5%)
subjects. Table 3 summarizes information about complete or
partial response, and treatment failure in adults and children
treated with ANA and CAN, distinguished by the pertinent
diagnosis.
The frequency of failure was significantly higher among
patients treated at a dosage of 100 mg/day than patients treated
with 2 mg/kg/day (p = 0.03). This finding was not maintained
when differentiating by the different treatment indications.
Regarding CAN, no statistical differences were identified in
complete response, partial response and failure according to the
different dosages administered (p = 0.43).
The mean ± SD duration of treatment was 24.4 ± 27 months
for both IL-1-INH, corresponding to 24.34 ± 27.03 months for
ANA and 24.52 ± 27.06 months for CAN, as well as 26.6 ±
28.6 months for pediatric patients and 24.39 ± 27.04 months for
adults. No significant differences were identified between adults
and children regarding treatment duration (p= 0.51).
Therapeutic Indications
As pointed-up in Table 4, IL-1-INH were administered due to 38
different indications, 37 for ANA and 16 for CAN. In pediatric
patients IL-1-INHwere administered for 16 different indications,
15 for ANA and 10 for CAN; in adults the therapeutic indications
were 36, 30 of which for ANA and 15 for CAN. Among patients
with complete response the different indications were 25, 23
FIGURE 3 | Use of concomitant therapies during IL-1 inhibition distinguishing by different indications. AOSD, Adult Onset Still’s Disease; BD, Behçet’s
Disease; CAPS, Cryopyrin-Associated Periodic Syndrome; CRMO, Chronic Recurrent Multifocal Osteomyelitis; FMF, Familial Mediterranean Fever; IRAP, Idiopathic
Recurrent Acute Pericarditis; RA, Rheumatoid Arthritis; SOJA, Systemic Onset Juvenile Idiopathic Arthritis; TRAPS, Tumor Necrosis Factor Receptor-Associated
Periodic Syndrome; USAID, Undifferentiated Systemic AutoInflammatory Disease.
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TABLE 2 | Previous and concomitant treatments administered to all patients.
Previous treatments Concomitant treatments
Corticosteroids (%) DMARDs (%) Biologics (%) Corticosteroids (%) DMARDs (%)
ALL 427/526 (81.17%) 310/526 (58.93%) 165/526 (31.36%) 285/526 (54.18%) 156/526 (29.65%)
AOSD 77/81 (95.06%) 60/81 (74.07%) 17/81 (20.98%) 66/81 (81.48%) 32/81 (39.50%)
SOJA 58/81 (71.60%) 38/81 (46.91%) 22/81 (27.16%) 44/81 (54.32%) 26/81 (32.09%)
BD 44/56 (78.57%) 43/56 (76.78%) 33/56 (58.92%) 41/56 (73.21%) 29/56 (51.78%)
RA 42/42 (100%) 42/42 (100%) 22/42 (52.38%) 35/42 (83.33%) 21/42 (50%)
FMF 30/38 (78.37%) 23/38 (59.45%) 13/38 (35.13%) 14/38 (36.84%) 12/38 (31.57%)
USAID 27/37 (72.97%) 23/37 (62.16%) 10/37 (27.02%) 14/37 (37.83%) 7/37 (18.91%)
CAPS 26/40 (65%) 16/40 (72.97%) 14/40 (35%) 4/40 (10%) 2/40 (5%)
TRAPS 27/35 (77.14%) 3/35 (8.57%) 9/35 (25.71%) 12/35 (34.28%) 1/35 (2.85%)
IRAP 21/23 (91.30%) 11/23 (47.82%) 0/23 (0.00%) 12/23 (52.17%) 7/23 (30.42%)
CRMO 7/11 (63.63%) 3/11 (27.27%) 1/11 (9.09%) 3/11 (27.27%) 2/11 (18.18%)
OTHERS 69/82 (81.36%) 48/82 (58.93%) 24/82 (31.36%) 40/82 (48.78%) 17/82 (20.73%)
AOSD, Adult Onset Still’s Disease; BD, Behçet’s Disease; CAPS, Cryopyrin-Associated Periodic Syndrome; CRMO, Chronic Recurrent Multifocal Osteomyelitis; FMF, Familial
Mediterranean Fever; IRAP, Idiopathic Recurrent Acute Pericarditis; RA, Rheumatoid Arthritis; SOJA, Systemic Onset Juvenile Idiopathic Arthritis; TRAPS, Tumor Necrosis Factor
Receptor-Associated Periodic Syndrome; USAID, Undifferentiated Systemic AutoInflammatory Disease; DMARDs, Disease Modifying Antirheumatic Drugs.
FIGURE 4 | Frequency of administration for different dosages employed with Anakinra (A) and Canakinumab (B).
of which for ANA and 12 for CAN. For patients with partial
response the indications were 25, 24 of which for ANA and
12 for CAN. Among patients with failing response the number
of indications was 22, 21 of which for ANA and 6 for CAN.
The number of indications for IL-1-INH was significantly higher
among adults than in pediatric subjects (p < 0.0001), but there
were no significant differences in the number of indications when
ANA and CAN were analyzed separately (p = 0.41 and p = 0.23,
respectively). There were no statistical differences in the number
of indications for patients with complete, partial, and failing
response neither on the total number of IL-1-INH (p= 0.71), nor
for ANA (p= 0.80) and CAN (p= 0.25).When ANA represented
the first anti-IL-1 approach, the number of indications stood
at 37, while for CAN as the first anti-IL-1 agent the number
of indications amounted to 13. Consequently, the number of
indications was significantly higher for patients undergoing ANA
as first IL-1-INH (p < 0.0001); Figure 5 represents the first-line
employment of ANA and CAN for the different indications.
Previous Treatments
ANA was employed as first line biologic approach in 323 (76.7%)
cases, while CAN was employed as first biologic in 37 cases
(35.2%). Consequently, the frequency of ANA administration as
first line biologic approach was significantly higher compared to
CAN (p < 0.0001). ANA and CAN were employed as second
biologic line in 52 (12.4%) and 42 (40%) cases, respectively; third
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TABLE 4 | List of indications for which IL-1 inhibitors were administered.
List of indications N◦ of treatments
ANAKINRA (421/526)
Adult onset Still’s disease 78/421(18.52%)
Ankylosing spondylitis 1/421(0.23%)
Autoinflammatory syndrome induced by adjuvants (ASIA)
syndrome
1/421(0.23%)
Behçet’s disease 41/421(9.73%)
Blau syndrome 1/421(0.23%)
Chondrocalcinosis 3/421(0.71%)
Chronic recurrent multifocal osteomyelitis 11/421(2.61%)
Cryopyrin-associated periodic syndromes 18/421(4.27%)
Familial Mediterranean fever 32/421(7.6%)
Gout 5/421(1.18%)
Histiocytic panniculitis 1/421(0.23%)
Hyper-IgD syndrome 5/421(1.18%)
Idiopathic recurrent acute pericarditis 23/421(5.46%)
Idiopathic uveitis 2/421(0.47%)
Juvenile idiopathic arthritis 4/421(0.95%)
Mevalonic aciduria 1/421(0.23%)
NLRP12-associated familial cold autoinflammatory disease 2/421(0.47%)
Osteoarthritis 1/421(0.23%)
Periodic fever 5/421(1.18%)
Periodic fever, aphthous stomatitis, pharyngitis, cervical
adenitis (PFAPA) syndrome
1/421(0.23%)
Polychondritis 1/421(0.23%)
Polyserositis 1/421(0.23%)
Psoriatic arthritis 1/421(0.23%)
PSTPIP1-associated myeloid-related-proteinaemia
inflammatory syndrome
1/421(0.23%)
Pyoderma gangrenosum 1/421(0.23%)
Pyogenic arthritis, pyoderma gangrenosum, acne (PAPA)
syndrome
2/421(0.47%)
Rheumatoid arthritis 42/421(9.97%)
SAPHO (synovitis, acne, pustulosis, hyperostosis, osteitis)
syndrome
3/421(0.71%)
Sarcoidosis 1/421(0.23%)
Schnitzler’s syndrome 7/421(1.66%)
Sweet’s syndrome 2/421(0.47%)
Systemic-onset juvenile idiopathic arthritis 57/421(13.53%)
Tumor necrosis factor receptor-associated periodic syndrome 21/421(4.98%)
Vasculitic urticaria 1/421(0.23%)
Undifferentiated connective tissue disease 4/421(0.95%)
Undifferentiated spondyloarthritis 1/421(0.23%)
Undifferentiated systemic autoinflammatory disease 31/421(7.36%)
CANAKINUMAB (105/526)
Adult onset Still’s disease 3/105(2.85%)
Behçet’s disease 15/105(14.28%)
Cryopyrin-associated periodic syndromes 22/105(20.95%)
Epidermolysis bullosa 1/105(0.95%)
Familial Mediterranean fever 6/105(5.71%)
Hyper-IgD syndrome 4/105(3.8%)
Idiopathic uveitis 2/105(1.90%)
(Continued)
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TABLE 4 | Continued
List of indications N◦ of treatments
Juvenile idiopathic arthritis 2/105(1.90%)
Mevalonic aciduria 1/105(0.95%)
NLRP12-associated familial cold autoinflammatory disease 2/105(1.90%)
Periodic fever 1/105(0.95%)
Periodic fever, aphthous stomatitis, pharyngitis, cervical
adenitis (PFAPA) syndrome
1/105(0.95%)
Systemic-onset juvenile idiopathic arthritis 24/105(22.85%)
Tumor necrosis factor receptor-associated periodic syndrome 14/105(13.33%)
Vasculitic urticaria 1/105(0.95%)
Undifferentiated systemic auto-inflammatory disease 6/105(5.71%)
line in 28 (6.7%) and 12 (11.4%) patients, respectively; fourth line
in 8 cases for ANA (1.9%) and 9 for CAN (8.6%); fifth line in 5
(1.2%) and 4 (3.8%) cases; more than fifth line in 5 (1.2%) and 1
(0.9%) cases. Table 5 displays the clinical outcome for ANA and
CAN used for different treatment lines.
Before starting IL-1-INH, corticosteroids had been already
employed in 428 out of 526 (81.4%) cases, 95 (22.2%) of which
were pediatric ones; DMARDs had preceded IL-1 inhibition in
309 cases (58.7%), 57 (18.4%) of which were pediatric ones. In
addition, 35 pediatric (21.2%) and 130 adult subjects (78.8%) had
been previously treated with at least one biologic agent different
from IL-1-INH. Table 2 shows details about previous therapeutic
approaches, while Figure 6 shows the amount of the specific
DMARDs and biologics previously administered.
Switching from a First to a Second Anti-Il-1
Agent
The number of patients switched from ANA to CAN was
significantly higher than patients switched from CAN to ANA
(p < 0.0001). Specifically, the number of patients firstly treated
with ANA and then switched to CAN amounted at 60 (57.1%);
conversely, although with a complete response, 2 (0.5%) patients
(diagnosed with SOJA and CAPS) needed to be switched from
CAN to ANA because of mild leukopenia and loss of efficacy,
respectively.
Reasons for switching from ANA to CAN were as follows: loss
of efficacy (n = 29, 48.3%) after a mean ± SD treatment period
of 25.97± 24.47 months, lack of compliance (n= 7, 11.7%), and
lack of efficacy (n = 6, 10%). However, no data were available
about the reason for ANA discontinuation in 18 (30%) patients
despite a treatment duration ranging from 3 to 132 months.
Regarding clinical outcome, complete response was achieved
in 40 (66.7%) cases switched from ANA to CAN, partial response
in 17 (28.3%) and failure in 3 (0.5%). Conversely, both patients
switched from CAN to ANA proved to be completely responsive
to the second anti-IL-1 agent.
Concomitant Treatments
IL-1-INH were associated with corticosteroids in 285 (54.2%)
cases, 244 patients being treated with ANA and 41 with CAN.
Concomitant DMARDs were employed in 156 (29.66%) cases,
of which 138 (88.46%) were using ANA and 18 (11.54%) CAN.
Methotrexate was employed in 67 (42.9%) patients, colchicine in
32 (20.5%), cyclosporine A in 25 (16.03%), hydroxychloroquine
in 12 (7.7%), salazopyrine in 7 (4.5%), leflunomide in 6 (3.8%),
azathioprine in 6 (3.8%), mycophenolate mofetil in 1 (0.6%) case.
In six cases more than one DMARD was associated with
IL-1 inhibition: colchicine plus hydroxychloroquine, colchicine
plus methotrexate, methotrexate plus leflunomide, methotrexate
plus cyclosporine A, and salazopyrine plus leflunomide each in
one case, respectively. Patients requiring two DMARDs were
diagnosed with BD (n = 3), SOJA (n = 1), polyarticular juvenile
idiopathic arthritis (n = 1), and RA (n = 1); these patients
were treated with ANA in all cases. Figure 7 graphically shows
the frequency of concomitant DMARDs and the distinction
according to ANA and CAN use.
Adverse Events
Seventy-six (14.4%) patients reported AEs and 10 (1.9%)
SAEs. Specifically, AEs included skin reactions (28 injection
site reactions, 5.3%; 29 generalized skin involvement, 5.5%),
disorders of hematopoiesis (n = 6, 1.15%), infections (n = 4,
0.7%), gastrointestinal affections (n= 2, 0.3%), flu-like symptoms
(n = 2, 0.4%), increase of aminotransferases (n = 1, 0.2%),
thrombophlebitis (n= 1, 0.2%), unspecified temporary breathing
problems (n = 1, 0.2%), unspecified problems (n = 2, 0.4%).
Seventy-two (94.7%) patients were on ANA and 4 on CAN
treatment.
AEs were significantly more frequent among patients
with concomitant therapy compared to patients with either
concomitant treatments (p = 0.01), or previous DMARDs
treatment (p= 0.04).
Distinguishing among different types of AEs, no significant
differences were found on the basis of previous and concomitant
therapies; in particular, no difference was found for skin reaction
among patients with or without previous DMARDs and/or
biologic treatment and patients with or without co-administered
DMARDs (p= 0.94).
SAEs recorded were as follows: pneumonia in three adult
patients with AOSD; trophic ulcers of lower limbs in one patient
with AOSD; herpetic keratitis in one patient with RA; and
anaphylaxis in four (0.6%). Finally, one patient with BD was
diagnosed with pleural mesothelioma after 3 months of ANA
treatment. Death occurred in five patients, all treated with ANA.
Nine out of 10 patients with SAEs were under ANA treatment.
Table 6 summarizes clinical characteristics of patients with SAEs
and in which death occurred.
Figure 8 shows the frequency of AEs in patients undergoing
ANA treatment; as regards CAN, skin rash (n = 3) and
gastrointestinal symptoms (diarrhea, abdominal pain; n = 2)
represented the most frequently recorded AEs; flu-like symptoms
(n = 1) and asthenia (n = 1) were also reported after CAN
administration.
When patients were subdivided into three age groups (<16
years, 16–65 years, and>65 years), AEs proved to be significantly
more frequent after the age of 65 compared to both pediatric
patients and subjects aged between 16 and 65 (p = 0.003 and p
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FIGURE 5 | First-line employment of Anakinra and Canakinumab in different indications differentiating between pediatric (A) and adult patients (B).
AOSD, Adult Onset Still’s Disease; BD, Behçet’s Disease; CAPS, Cryopyrin-Associated Periodic Syndrome; CRMO, Chronic Recurrent Multifocal Osteomyelitis; FMF,
Familial Mediterranean Fever; IRAP, Idiopathic Recurrent Acute Pericarditis; RA, Rheumatoid Arthritis; SOJA, Systemic Onset Juvenile Idiopathic Arthritis; TRAPS,
Tumor Necrosis Factor Receptor-Associated Periodic Syndrome; USAID, Undifferentiated Systemic AutoInflammatory Disease.
= 0.03, respectively). Table 7 describes the frequency of different
AEs according to the age of patients.
In 61 (71.8%) cases AEs led to treatment discontinuation, in
59 cases treated with ANA and in two cases treated with CAN.
Regarding patients remaining under ANA treatment despite AEs,
most were characterized by injection site reactions (n = 13);
others were interested by infections (otitis, n = 1; infection of
the upper respiratory tract, n = 1; bronchitis, n = 1; pneumonia,
n = 1), transient leukopenia (n = 1), thrombophlebitis (n
= 1), widespread skin rash with eosinophilia (n = 1). Patients
continuing CAN despite AEs had presented localized cutaneous
erythema (n= 2) and flu-like symptoms (n= 1).
Dose Adjustments
Dose adjustments were performed for 117 treatment cycles
(22.4%), 88 (75.2%) for ANA and 29 (24.8%) for CAN; no
statistical differences were identified in the number of dose
adjustments between ANA and CAN (p= 0.29).
Regarding subjects treated with ANA, an increase of the
dose was performed in 12 cases, bringing about a recovery of
effectiveness in 7 (58.3%) cases. Conversely, a decrease of the
dosage was attempted in 76 patients, leading to maintenance of
therapeutic efficacy in 89.4% (n = 68) of cases. Among patients
treated with CAN, an increase of dosage was performed in 15.2%
(n= 16) of patients, obtaining a recovery of efficacy in 10 (62.5%).
On the contrary, a reduction of dosage was attempted in 12
(11.4%) subjects, leading to maintenance of efficacy in 11 cases
out of 12 (91.6%). One patient (0.9%) with TRAPS underwent
an increase of the interval between CAN administrations without
changing the dosage and without losing efficacy. Figure 9 shows
the number of patients undergoing an increase/decrease of IL-1
INH dosage with related clinical outcome.
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Reasons for Discontinuation
Discontinuation of anti-IL-1 regimen was performed in 246
(46.6%) cases, 225 (91.5%) while on ANA and 21 (8.5%) on CAN.
The reasons for discontinuation were as follows: loss of efficacy (n
= 75, 30.4%), lack of efficacy (n = 57, 23.2%), disease remission
(n = 38, 15.4%), occurrence of AEs (n = 33, 13.4%) and SAEs
(n = 7, 2.9%), poor compliance (n = 14, 5.6%), death (n = 5,
2%), pregnancy (n = 2, 0.8%). Eight cases (3.2%) were lost at
follow-up. Figure 10 shows the reasons for discontinuation by
distinguishing between ANA and CAN. As this figure shows, the
percentage of poor compliance is higher in patients treated with
CAN, though no statistical significance was reached (p= 0.49).
DISCUSSION
In this study, we aimed at evaluating how IL-1-INH are
currently used in a group of Italian rheumatological and
pediatric Centers, principally in terms of therapeutic indications,
dosages employed, clinical management, and safety issues, thus
identifying differences between adults and patients aged <16
years. In particular, by virtue of the large number of patients
enrolled, we would provide useful real-life-related data for the
physician needing to resort to IL-1 inhibition.
To date, therapeutic indications for ANA include only RA and
CAPS, while on-label use of CAN refers to CAPS, SOJA, and gout.
Nevertheless, thanks to vivid basic and clinical research efforts,
innate immunity has recently proven to have an important
role in a wide number of disorders beyond monogenic AIDs
(Banerjee and Saxena, 2012; Dickie et al., 2012; Vitale et al.,
2012; Caso et al., 2013; Sheedy and Moore, 2013; Van Tassell
et al., 2013; Baskar et al., 2016). Sure enough, inflammatory
pathways of innate immunity have been found to affect a lot
of pathologies previously classified as exclusively belonging to
the field of adaptive immune disorders or degenerative diseases
(Martinon et al., 2006; Rigante et al., 2011; Kotas et al., 2013;
Ruscitti et al., 2015; Thueringer et al., 2015). Consequently, in
the last years a large number of old and new clinical entities
have been suggested as possible further therapeutic indications
for IL-1-INH (Cantarini et al., 2010, 2015b; Caso et al., 2014;
Finetti et al., 2014; D’Elia et al., 2015; Imazio et al., 2016).
Therefore, whilst now it is absolutely clear that tumor necrosis
factor (TNF)-inhibitors represent a therapeutic option of first
order compared to IL-1-INH in RA, a resurgence of interest has
occurred for these agents to treat a wide number of diseases
located somewhere along a continuity of aberrant innate or
adaptive immune responses (Larsen et al., 2007;McGonagle et al.,
2007; Shin et al., 2009; Tanzi et al., 2011; Abbate et al., 2013; de
Koning et al., 2013; Howard et al., 2014; Néel et al., 2014; Van
Tassell et al., 2014; Lopalco et al., 2015b, 2016; Vitale et al., 2015;
Annicchiarico et al., 2016).
In this context, Rossi-Semerano et al. (2015) have recently
published an interesting national cross-sectional observational
study on 189 patients from 38 France Centers. As for our results,
they also observed that AOSD and SOJA represented the clinical
conditions more frequently requiring IL-1-INH; also, ANA was
more commonly employed than CAN with off-label modality.
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FIGURE 6 | Amount of specific disease modifying antirheumatic drugs/corticosteroids (A) and biologic agents (B) previously administered. ABA,
abatacept; ADA, adalimumab; AZA, azathioprine; COL, colchicine; CycA, cyclosporine A; CZP, certolizumab pegol; INX, infliximab; ETN, etanercept; GCC,
glucocorticoids; GOL, golimumab; HCQ, hydroxychloroquine; LFN, leflunomide; MTX, methotrexate; RTX, rituximab; SSZ, sulfasalazine; TCZ, tocilizumab.
Regarding clinical outcome, they found a higher response rate
among patients suffering from Schnitzler’s syndrome, gout,
CAPS, and AOSD. Both ANA and CAN appeared safe as for
our patients: most of AEs were classified as minor, while most
of the time SAEs were represented by severe infections. However,
while Rossi-Semerano et al. (2015) observed a number of patients
with liver abnormalities and weight gain, we identified only one
case of liver toxicity and did not observe any case of weight
increase.
Coming back to our study, in our experience most of
treatment courses were due to off-label indications, ranging
from different monogenic AIDs to a wide variety of polygenic
and multifactorial disorders, as summarized in Table 4. This is
evident for both IL-1-INH, but as for Rossi-Semerano et al.
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FIGURE 7 | Frequency of disease modifying antirheumatic drugs
(DMARDs) concomitantly administered with Anakinra (A) and
Canakinumab (B). DMARDs, disease modifying antirheumatic drugs.
(2015), the percentage of off-label use was significantly higher
among patients treated with ANA. We think that this is
probably related to the high manageability of ANA and to its
shorter half-life (Church and McDermott, 2009), but also to the
longer experience gained with ANA, and perhaps to cost-related
implications. As a whole, the number of different indications
for IL-1-INH was significantly higher in adults than in pediatric
patients, suggesting that the off-label use of ANA and CAN
is more frequently advised by adult health care physicians.
However, we did not find statistical differences in the number
of indications among patients presenting with complete, partial
and failing response, concluding that IL-1-INH are used with
awareness of pathogenetic mechanisms also when administered
with off-label modality.
In addition to the large number of therapeutic indications, the
off-label use of IL-1-INH also manifests with a wide variability
of dosages administered both among children and adults.
Noteworthy, dosages were more frequently employed based on
the body weight among pediatric patients, while adults were
more frequently treated with standard dosages. On the contrary,
teenage patients (aged <16 years) were frequently treated with a
standard dose, as occurring in adults, as a result of the transition
from pediatric to adult health care. However, since the body
weight affects the pharmacokinetics of drugs (Urien et al., 2013),
the two different modalities of IL-1-INH administration may
influence the degree of effectiveness. In this regard, we found
that the frequency of failure was significantly higher among
patients treated with ANA at the dosage of 100mg/day compared
to dosage of 2 mg/kg/day. Conversely, no similar results were
identified for CAN, probably due to a lower impact of the
body weight related to the much longer half-life (Church and
McDermott, 2009), but also to the tiny sample sizes obtained after
dividing our CAN population for different dosages.
As expected, we observed that the number of patients switched
from ANA to CAN was significantly higher than vice versa,
as a likely result of the higher costs of CAN and, here again,
of the easy handling of ANA. In fact, the little experience to
date available in the off-label context and the relatively scarce
supporting literature set physicians advising ANA for safety
reasons. Nevertheless, data available on CAN safety (Alten et al.,
2011; Ruperto et al., 2012a,b; Imagawa et al., 2013; Howard et al.,
2014; Gül et al., 2015), also supported by the present study, make
switching from CAN to ANA a reasonable medical choice. In
addition, our results demonstrate that patients requiring being
moved-on from CAN to ANA showed a complete response after
the change of therapy. However, switching between the two IL-1-
INH represents a concrete and effective therapeutic opportunity
in both directions. Indeed, only 0.5% of patients needing to be
switched from ANA to CAN showed a failure after change of
therapy, and two-thirds of subjects converted from ANA to CAN
even showed a complete response. Consequently, these results
confirm previously reported data on the concrete and effective
role of switching from a first to a second IL-1-targeted inhibitor
(Brizi et al., 2012; Galeotti et al., 2012; Cantarini et al., 2015b;
Lopalco et al., 2015b; Emmi et al., 2016).
Similarly, adjusting IL-1-INH dosages by increasing the
dose at each administration or decreasing the timing between
injections have proved to be successful choices in 66.7% of
patients treated with ANA or CAN. These findings suggest that
increasing the dosage of IL-1-INH in patients with unsatisfactory
results can be a feasible therapeutic strategy. On the other hand,
decreasing the dosage in patients with sustained drug-induced
quiescence seems to represent another possible way to go when
the clinical condition is suitable. Indeed, 92.9% of patients treated
experienced maintenance of complete response despite the dose
tapering.
Regarding which agent physicians chose as a first option, ANA
was employed as first line biologic agent in a greater number of
patients, probably due to the higher use of this drug in off-label
prescription in reference to the aforementioned explanations.
Similarly, the number of DMARDs administered before and
during IL-1-INH reflects the frequency with which ANA and
CANwere prescribed for complex and multifactorial indications.
Actually, the frequency of concomitant and previous DMARDs
was higher in adults than pediatric patients and in the population
treated with ANA. These findings confirms that IL-1-INH are
more likely aimed at treating multifactorial disorders in such
cases, whose pathogenesis involves different cell and cytokine
pathways and often requires a combination therapy rather than
monotherapy. Read backward, these data also suggest that during
childhood IL-1-INH (especially CAN) are more frequently used
in monogenic AIDs, generally not requiring DMARDs.
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As a whole, AEs and SAEs interested one-sixth and 1.7%
of patients, thus confirming the good safety profile of IL-1-
INH. Interestingly, patients with previous or concomitant use of
DMARDs showed a higher frequency of AEs, probably due to
the intrinsic safety issues related to the additional employment
of DMARDs as well as to the wide number of clinically complex
diseases requiring additional immunosuppressive therapies.
However, we did not observe any impact of DMARDs on the
occurrence of skin reactions. This is an interesting finding, as our
results are the opposite of that presented by Rossi-Semerano et al.
(2015).
In any case, according to the previous experience with
ANA, skin reactions did not lead to treatment discontinuation,
confirming that this kind of AEs are usually transient and
improves after the first weeks of treatment, with no need for ANA
withdrawal (Lequerré et al., 2008).
As we look at SAEs, 40% of them were represented by
anaphylactic reactions occurring in three patients treated with
ANA and one patient treated with CAN. The other SAEs were
FIGURE 8 | Frequency of adverse events in patients undergoing
Anakinra.
severe bacterial infections in three cases, one case of severe
herpetic keratitis, and one case of pleural mesothelioma. Death
occurred in five cases, two of which as a consequence of infectious
SAEs (pneumonia in both cases). However, these infections
appeared more likely related to the existing comorbidities
and to the globally poor clinical condition than to an actual
compromising effect of ANA. In particular, two cases of severe
infections had been diagnosed with AOSD and one case with
SAPHO syndrome; moreover, AOSD represented the indication
requiring IL-1-INH in four out of five cases in whom death
occurred. In this regard, the mortality rate in AOSD is reported
in up to 10% of patients and overwhelming infections (as also the
macrophage activation syndrome and the myocarditis reported
in two of our dead patients) represent a major cause of death.
Pneumonia itself has been identified as a frequent cause of
mortality and an unfavorable prognostic factor in AOSD (Zeng
et al., 2009; Kim et al., 2012). Conversely, the dynamics of
death of the patient with SAPHO were not completely clear, and
we cannot explain in which context pneumonia led to death.
Finally, the case of pleural mesothelioma was diagnosed after
only 3 months of ANA administration, so we do not ascribe any
cancerogenetic effect to IL-1 inhibition.
An intriguing finding of the present study was represented
by the significant higher occurrence of AEs in subjects aged
more than 65 years than in others, children included. This result
conflicts with the evidence reported by Rossi-Semerano et al.
(2015), identifying a higher incidence of AEs among children
than in adults. Since no notable differences exist between the two
studies in terms of percentages of pediatric and adult patients,
this difference could be explained by the higher number of
indications observed in our population. Consequently, while a
careful monitoring should be guaranteed for all patients, elderly
subjects could deserve a closer follow-up, especially for poorly
investigated indications.
Noteworthy, none of our patients experienced tuberculosis
infection or reactivation, corroborating our previous results on
the same matter (Cantarini et al., 2015a; Lopalco et al., 2016)
and suggesting that use of IL-1-INH is relatively safe compared
TABLE 7 | Frequency of different adverse events and severe adverse events according to the age of patients.
Age (years) N◦ treatments Total reactions Generalized
skin reaction
Injection site
reaction
Hematopoiesis
disorders
Infection Gastrointestinal
involvement
Anaphylaxis Other
ADVERSE EVENTS AND SEVERE ADVERSE EVENTS (DIVIDED BY AGE)
Total number of AEs: 76 out of 526 treatments
All Ages 526 76 (14.44%) 29 28 6 4 2 – 7
0–15.99 130 11 (8.46%) 1 7 – – 1 – 2
16–64.99 331 50 (15.1%) 22 16 3 4 1 – 4
≥65 65 15 (23.07%) 6 5 3 – – – 1
Total number of SAEs: 10 out of 526 treatments
All Ages 526 10 (1.9%) – – – 4 – 4 2
0–15.99 130 3 (2.3%) – – – – – 3 –
16–64.99 331 4 (1.2%) – – – 2 – 1 1
≥65 65 3 (4.61%) – – – 2 – – 1
AEs, Adverse Events; SAEs, Severe Adverse Events.
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FIGURE 9 | Number of patients undergoing an increase or decrease of IL-1 INH dosage with related clinical outcome.
FIGURE 10 | Reasons for discontinuation distinguishing between
Anakinra (A) and Canakinumab (B).
to other therapeutic tools in those geographical areas where
tuberculosis is an endemic issue.
Because of the retrospective design, this study has some
limitations: firstly, although data collection was quite exhaustive,
some information was lacking due to the inability to collect
all clinical data. This was especially true about the reasons
for discontinuation, which remained without explanation in
18 cases treated with ANA. Secondly, a limitation of the
causality assessment is highly probable in a retrospective study.
In addition, the huge number of therapeutic indications made
impossible a sharp statistical analysis on the response to IL-
1-INH. Indeed, fragmentation of cases among 38 different
indications and three possible outcomes (complete response,
partial response, and failure) led to small sample sizes and
convincing conclusions could not be drawn. As a result, we
performed an overall description on the response and placed
the issue of clinical response among the ancillary end-points.
However, this is the first study showing how and when IL-1-INH
are prescribed in Italy, highlighting different therapeutic choices
in terms of starting dosages, dose adjustments, and switching
from one to another IL-1-INH as well as the assessment of safety
profile on a large number of patients.
In conclusion, our data show that treatment with IL-1-
INH is mostly used in off-label regimen. Nevertheless, the
high amount of complete and partial clinical response obtained
suggests that IL-1-INH are administered in clinical conditions
mostly characterized by the pathogenetic involvement of IL-
1 cytokine network. Accordingly, most of the patients were
concomitantly treated with DMARDs and had been previously
administered with other biologic agents different from IL-
1-INH, especially anti-TNF drugs. The off-label use of IL-
1-INH has been more frequent for ANA and for adult
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patients. The wide spectrum of dosages administered for IL-
1-INH is a further interesting information emerging from
our data: while adult health care physicians generally employ
standard dosages of IL-1-INH, pediatricians are more frequently
inclined to use a weight-based posology, which seems to be a
more adequate therapeutic strategy because of pharmacokinetic
implications about drug-tissue concentrations. Furthermore,
switching from a first to a second IL-1-INH and increasing
dosages appear to be useful in order to obtain a more
successful clinical response. According to our findings, switching
from CAN to ANA is a less common therapeutic choice
than the reverse. However, patients undergoing this procedure
showed complete response, and consequently we think that
this therapeutic option should be kept into much greater
account. The present study confirms the good safety profile
of IL-1-INH in terms of low risk of tuberculosis. In addition,
the majority of AEs were mild or moderate and did not
require treatment discontinuation. On the other hand, SAEs
and deaths reported were mostly connected to the underlying
disease or other comorbidities. Finally, our data show that a
slightly closer follow-up may be useful in patients over 65 years
of age.
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